Early Positive Biomarker in Relation to Myocardial Necrosis and Impaired Fatty Acid Metabolism in Patients Presenting With Acute Chest Pain at an Emergency Room

Nagahara, Daigo; Nakata, Tomoaki; Hashimoto, Akiyoshi; Takahashi, Toru; Kyuma, Michifumi; Hase, Mamoru; Tsuchihashi, Kazufumi; Shimamoto, Kazuaki

doi:10.1253/circj.70.419

Cited by 21 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…h-FABP levels were higher in the pericardial fluid but not in the serum of patients who presented with UA within the 24 hours prior to surgery, compared with other patients without acute myocardial ischemia. In another study, Nagahara et al 39 reported four h-FABP-positive serum assays out of 13 patients with UA. We confirmed that CardioDetect is not a sensitive test for minor myocardial injury in patients with UA.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Charpentier

Ducassé

Cournot

et al. 2010

Academic Emergency Medicine

View full text Add to dashboard Cite

Objectives: Heart fatty acid-binding protein (h-FABP) and ischemia-modified albumin (IMA) have recently been evaluated, but to the best of our knowledge, no study has reported an analysis of these two markers for the detection of early myocardial infarction and myocardial ischemia in a large cohort of consecutive patients presenting to an emergency department (ED). This study evaluates the diagnostic accuracy and the clinical utility of h-FABP and IMA for non-ST-segment elevation acute coronary syndrome (ACS) diagnosis in the first hour of management in an ED.Methods: In a prospective 11-month study, 677 patients admitted to the ED with chest pain and suspected non-ST-segment elevation ACS were enrolled. On presentation, blood samples were obtained for the measurement of the biomarkers h-FABP (immunodetection with CardioDetect) and IMA (albumin cobalt-binding test). Two physicians, blinded to the results of the markers, independently categorized patients as having or not having non-ST-segment elevation ACS.Results: Of the 677 patients who were prospectively recruited, non-ST-segment elevation ACS was diagnosed in 185 (27.3%). While IMA was not predictive of the ACS diagnosis (odds ratio [OR] = 1.23; 95% CI = 0.87 to 1.81), h-FABP was predictive of ACS diagnosis (OR = 4.65; 95% CI = 2.39 to 9.04) with specificity at 96.8% (95% CI = 95.4% to 98.1%) and sensitivity at 13.5% (95% CI = 10.9% to 16.1%). However, h-FABP did not add significant additional information to a predictive model that included the usual diagnostic tools for non-ST-elevation ACS management (p = 0.40). Conclusions:In this study on a large cohort of patients admitted to an ED for chest pain, IMA and h-FABP did not provide valuable information for ACS diagnosis.

show abstract

Section: Discussionmentioning

confidence: 97%

“…39 Although their agreement was high, it was not perfect. The diagnosis of unstable angina can be difficult, and diagnostic tests were done only for a minority of ACS troponin-negative patients after ED discharge.…”

Section: Limitationsmentioning

confidence: 99%

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Charpentier

Ducassé

Cournot

et al. 2010

Academic Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…Molecular size and intracellular location are also important factors determining the plasma kinetic release of cardiac biomarkers. Small cytoplasmic molecules H-FABP (15 kD) rise earlier (2-4 h) than bigger ones mainly associated with myofibrils as cardiac troponins (6-12 h) [4,5]. Therefore, H-FABP has been used diagnostic marker for acute coronary syndromes.…”

Section: Introductionmentioning

confidence: 99%

Serum heart type fatty acid binding protein levels in metabolic syndrome

Akbal

Özbek

Güneş

et al. 2009

Endocr

View full text Add to dashboard Cite

Heart type fatty acid binding protein (H-FABP) is a major cytoplasmic low-molecular weight protein and released into the circulation when the myocardium is injured. Previous studies have demonstrated that H-FABP is closely associated with acute coronary syndrome, hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea syndrome, pulmonary embolism. The aim of this study was to investigate serum H-FABP value in the patients with metabolic syndrome (MetS). We measured serum H-FABP levels in 55 consecutive patients with MetS, and 73 age-matched control subjects by using a sandwich enzyme-linked immunosorbent assay. Serum H-FABP levels were significantly higher in patients with MetS than in control subjects 18.37 ± 13.0 and 7.9 ± 6.5 ng/ml, respectively, (P < 0.001). Serum H-FABP levels were significantly higher in patients with diabetic MetS than in without diabetic MetS, 24.0 ± 10.2 and 13.9 ± 12.6 ng/ml, respectively, (P: 0,003). There were statistically significant differences between patients without diabetic MetS and control subjects, 13.8 ± 12.6 and 7.9 ± 6.5 ng/ml, respectively, (P = 0.023). Patients with MetS have an increased risk of death from cardiovascular diseases. H-FABP seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in patients with MetS.

show abstract

“…H-FABP represents 10% of the whole cardiac myocytes cytosolic protein (7). As such, there are data documenting the diagnostic utility of H-FABP and ischemia-modified albumin (IMA) as early markers of ACS (14)(15)(16)(17)(18)(19). This study was prospectively designed to determine whether the combination of measuring H-FABP and IMA after onset of chest pain could effectively diagnose the patients with ACS and normal cardiac troponin T. sequential basis, patients who arrived at the emergency departments (ED) within 12 hr after the onset of chest pain.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of combination of heart‐type fatty acid‐binding protein and ischemia‐modified albumin in patients with acute coronary syndromes and normal troponin T values

Liyan

Zhang

2009

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Recent studies have suggested that hearttype fatty acid-binding protein (H-FABP) may detect ongoing myocardial damage involved in the progression of acute coronary syndromes (ACS). This study was prospectively designed to examine whether the combination of H-FABP, a marker for ongoing myocardial damage, and ischemia-modified albumin (IMA), a marker for myocardial ischemia, would effectively diagnose patients with ACS. H-FABP values above 1.5 mg/l can be correctly measured via an ELISA and 6 mg/l is the currently used cut-off value (1-3). We measured serum H-FABP and IMA of 108 patients on admission within 12 hr after onset of chest pain and normal troponin T. serum samples from ACS group (n 5 82) had decreased capacity of ACB [64 (61-67

show abstract

Early Positive Biomarker in Relation to Myocardial Necrosis and Impaired Fatty Acid Metabolism in Patients Presenting With Acute Chest Pain at an Emergency Room

Cited by 21 publications

References 28 publications

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Clinical Assessment of Ischemia‐modified Albumin and Heart Fatty Acid–binding Protein in the Early Diagnosis of Non‐ST‐elevation Acute Coronary Syndrome in the Emergency Department

Serum heart type fatty acid binding protein levels in metabolic syndrome

Prognostic value of combination of heart‐type fatty acid‐binding protein and ischemia‐modified albumin in patients with acute coronary syndromes and normal troponin T values

Contact Info

Product

Resources

About